VERONA PHARMA PLC - AM

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

06 May 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

29 Apr 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

15 Apr 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

28 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

27 Feb 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces March 2025 Investor Conference Participation

18 Feb 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

13 Feb 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

07 Jan 2025 03:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces December 2024 Investor Conference Participation

18 Nov 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies London Healthcare Conference

04 Nov 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

03 Nov 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

20 Oct 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

29 Sep 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

04 Sep 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07 Aug 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

29 Jul 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

24 Jul 2024 23:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

26 Jun 2024 13:57:26 By Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 04:15:00 By Nasdaq GlobeNewswire

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

09 May 2024 04:00:01 By Nasdaq GlobeNewswire